Bill Oxford/E+ via Getty Images Bristol-Myers Squibb ( NYSE: BMY ) and Sanofi ( NASDAQ: SNY ) must pay more than $916M to Hawaii authorities for failing to warn of the health risks of their anticoagulant Plavix for non-white people, a judge in the state's First Circuit Court ruled on Tuesday. The ruling by Judge James Ashford follows the second trial related to the case after the state's Supreme Court determined that the judge who presided over the first trial had made an error in ordering the companies to pay over $834M in 2021. In 2014, Hawaii authorities alleged that the companies infringed upon the state's consumer protection laws by marketing the drug without disclosing its lack of efficacy for certain ethnicities, especially people of East Asian and Pacific Island ancestry.
Bristol-Myers ( BMY ) and Sanofi ( SNY ) disagreed with the ruling and said they would file an appeal. The companies added, "The overwhelming body of scientific evidence demonstrates that Plavix is a safe and effective therapy, regardless of a patient's race or genetics." The duo faces a similar case in New Mexico related to Plavix.
More on Bristol-Myers, Sanofi, etc. Bristol-Myers Squibb Company (BMY) Bank of America Global Healthcare Conference 2024 Transcript Bristol-Myers Squibb Company (BMY) Presents at Guggenheim Securities Radiopharmaceuticals Day (Transcript) Bristol-Myers Squibb: A Lost Decade? Bristol-Myers says FDA has revised decision date on injected Opdivo Sanofi teams up with Formation.
